Tom Schoenherr is the CEO, Ambry Genetics. Ambry Genetics was acquired by Tempus in 2025. Tom joined Ambry Genetics in 2017 as Chief Commercial Officer, where he led the execution of the company’s go-to-market strategy and oversaw all commercial functions, including service, support, sales, marketing, business development, managed care, and the genetic specialist team. With over 20 years of leadership experience in the molecular diagnostics space, Tom has held executive roles at several prominent organizations. Prior to Ambry, he served as Chief Commercial Officer at Omada Health, where he was responsible for driving business growth and expanding market share. He also held senior leadership positions at Counsyl, Quest Diagnostics, Siemens Healthcare, and Abbott Diagnostics. Tom holds a Bachelor of Science degree from Michigan State University and completed the Executive Business Development Program at the University of Notre Dame.